154 related articles for article (PubMed ID: 24647041)
1. Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity.
Muroi Y; Saito T; Takahashi M; Sakuyama K; Niinuma Y; Ito M; Tsukada C; Ohta K; Endo Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2014; 29(5):360-6. PubMed ID: 24647041
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Saito T; Gutiérrez Rico EM; Kikuchi A; Kaneko A; Kumondai M; Akai F; Saigusa D; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Dec; 33(6):250-257. PubMed ID: 30366777
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen.
Hu XX; Zhou Q; Lan T; Huang XX; Liang BQ; Dai DP; Cai JP; Hu GX
J Pharm Pharmacol; 2016 Jun; 68(6):819-25. PubMed ID: 27109434
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
6. Effect of 22 Novel Cytochrome P450 2D6 (CYP2D6) Variants Found in the Chinese Population on Hemangeol Metabolism In Vitro.
Liang B; Zhan Y; Huang X; Gu E; Dai D; Cai J; Hu G
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):759-765. PubMed ID: 26542054
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Fang P; Zheng X; He J; Ge H; Tang P; Cai J; Hu G
Drug Des Devel Ther; 2017; 11():1283-1290. PubMed ID: 28461741
[TBL] [Abstract][Full Text] [Related]
9. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2D6 variants on venlafaxine metabolism in vitro.
Zhan YY; Liang BQ; Wang H; Wang ZH; Weng QH; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):424-9. PubMed ID: 26406933
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
12. Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro.
Weng Q; Liang B; Zhou Y; Li X; Wang H; Zhan Y; Dai D; Cai J; Hu G
Pharm Biol; 2016 Nov; 54(11):2475-2479. PubMed ID: 27097346
[TBL] [Abstract][Full Text] [Related]
13. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 24 CYP2D6 Variants on the Metabolism of Nebivolol In Vitro.
Hu X; Lan T; Dai D; Xu RA; Yuan L; Zhou Q; Li Y; Cai J; Hu G
Drug Metab Dispos; 2016 Nov; 44(11):1828-1831. PubMed ID: 27538917
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP2D6 genetic polymorphism on the metabolism of citalopram in vitro.
Hu XX; Yuan LJ; Fang P; Mao YH; Zhan YY; Li XY; Dai DP; Cai JP; Hu GX
Drug Metab Pharmacokinet; 2016 Apr; 31(2):133-8. PubMed ID: 27016952
[TBL] [Abstract][Full Text] [Related]
18. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations.
Bapiro TE; Hasler JA; Ridderström M; Masimirembwa CM
Biochem Pharmacol; 2002 Nov; 64(9):1387-98. PubMed ID: 12392820
[TBL] [Abstract][Full Text] [Related]
19. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
20. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
